Brief: Biophytis Flags False Report On Sarconeos COVID-19 Study In Brazil

Biophytis SA

14/04/2021 09:03

April 14 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * SAID ON TUESDAY HAS BEEN MADE AWARE OF A FALSE REPORT
REGARDING
STATUS OF ITS COVA STUDY OF ITS SARCONEOS (BIO101) TREATMENT IN
COVID-19 IN BRAZIL
    * ON APRIL 12, AN ARTICLE WAS RELEASED VIA WBOC UNBEKNOWNST
TO
BIOPHYTIS; SAYS PRESS RELEASE WAS MISLEADING AND RELEASED
WITHOUT CO'S KNOWLEDGE BY UNKNOWN SOURCES 
    * BIOPHYTIS DID NOT WRITE, RELEASE NOR APPROVE THIS PRESS
RELEASE,
AND HAS REPORTED THIS TO PROPER AUTHORITIES AND WBOC
    * MOST RECENT NEWS ON THE COVA TRIAL IS THAT INDEPENDENT
DATA
MONITORING COMMITTEE(DMC) DELIVERED FAVORABLE OPINION ON SAFETY
OF SARCONEOS IN PATIENTS WITH COVID-19    

   
 Source text: https://bit.ly/3tjh9qL
 Further company coverage:  ALBPS.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))